EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy

Sajjad Ahmadpour, Mohammad Amin Habibi, Farzaneh Sadat Ghazi, Mikaeil Molazadeh, Mohammad Reza Pashaie, Yousef Mohammadpour

Cancer Treatment and Research Communications · 2024

DOI: 10.1016/j.ctarc.2024.100823 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2024. Verfasst von Sajjad Ahmadpour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Carcinogenesis, Disease Progression. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Urmia University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumors can produce bioactive substances called tumor-derived supernatants (TDS) that modify the immune response in the host body. This can result in immunosuppressive effects that promote the growth and spread of cancer. During tumorigenesis, the exudation of these substances can disrupt the function of immune sentinels in the host and reinforce the support for cancer cell growth. Tumor cells produce cytokines, growth factors, and proteins, which contribute to the progression of the tumor and the formation of premetastatic niches. By understanding how cancer cells influence the host immune system through the secretion of these factors, we can gain new insights into cancer diagnosis and therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsCarcinogenesisDisease ProgressionHumansTumor MicroenvironmentAnimalsCytokines

Stichwörter der Autor:innen

Cancer immunotherapyHost immune systemPremetastasis nicheTumor microenvironmentTumor-derived supernatantsTumorigenesis

Substanzen

Cytokines

Autor:innen und Institutionen

  • Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
  • Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Student Research Committee, Qom University of Medical Sciences, Qom, Iran.
  • Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran; Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
  • Department of Medical Education, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: mohammadpour.yousef@gmail.com.

Förderung

  • Urmia University of Medical Sciences

Zitieren

APA

Ahmadpour, S., Habibi, M. A., Ghazi, F. S., Molazadeh, M., Pashaie, M. R., & Mohammadpour, Y. (2024). The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2024.100823

Vancouver

Ahmadpour S, Habibi MA, Ghazi FS, Molazadeh M, Pashaie MR, Mohammadpour Y. The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy. Cancer Treatment and Research Communications. 2024. doi:10.1016/j.ctarc.2024.100823

BibTeX
@article{Ahmadpour2024,
  author = {Ahmadpour, Sajjad and Habibi, Mohammad Amin and Ghazi, Farzaneh Sadat and Molazadeh, Mikaeil and Pashaie, Mohammad Reza and Mohammadpour, Yousef},
  title = {The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy},
  journal = {Cancer Treatment and Research Communications},
  year = {2024},
  doi = {10.1016/j.ctarc.2024.100823}
}
Kostenlos starten →